medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Number 4

<< Back Next >>

Ann Hepatol 2003; 2 (4)

New therapies on the horizon for hepatitis C

Sookoian SC

Language: English
References: 24
Page: 164-170
PDF size: 75.58 Kb.


Text Extraction

Therapy of chronic HCV infection has greatly improved in recent years with the addition of ribavirin to alpha interferon and has further improved more with the use of PEG-interferons. However, more than half of patients do not achieve lasting benefits from these therapies. The future therapeutic developments may include one or more of the following approaches: understanding the HCV genomic organization, elucidating the viral life cycle and HCV replication strategy and understanding the immune mechanisms required for viral propagation or infectivity. The development of novel antiviral strategies and a preventive vaccine against HCV infection remains a major challenge for the future, and will depend on progress on both molecular biology as well as clinical studies. Unfortunately, the low replication of the virus in culture, the lack of convenient animal models, and the high genome variability present mayor challenges for drug development.


REFERENCES

  1. Alter MJ. Epidemiology of Hepatitis C. Hepatology 1997; 26(Suppl 1): 62S-65S.

  2. Penin F. Structural biology of hepatitis C virus. Clin Liver Dis 2003; 7(1): 1-21.

  3. Cho PW, Westaway EG. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semi conservative and asymmetric replication. Virology 1985; 140: 68-79.

  4. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100(12): 7271-6.

  5. Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foung S, Amara A, Houles C, Fieschi F, Schwartz O, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 2003; 30; 278(22): 20358-66.

  6. Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA 2003; 15; 100(8): 4498-503.

  7. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, et al. Crystal structure of hepatitis virus NS3 proteinase domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87: 331-355.

  8. Barbato G, Cicero DO, Nardi MC, Steinkuhler C, Cortese R, De Francesco R, Bazzo R. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein derives new insights into its activation and catalytic mechanisms. J Mol Biol 1999;289:371-384.

  9. Yao N, Hesson T, Cable M, Hong Z, Kwong AD, Le HV, Weber PC. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997; 4(6): 463-7.

  10. Zhang X. Inhibitors of hepatitis C: a review of the recent patent literature. I Drugs 2002; 5: 154-158.

  11. Randall G, Grakoui A, Rice ChM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs . Proc Natl Acad Sci USA 2003, 7; 100(1): 235-40.

  12. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L, Kurosaki M, Taira K, Watanabe M, Mizusawa H. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003; 4(6): 602-8.

  13. Vidalin O, Major ME, Rayner B, Imbach JL, Trepo C, Inchauspe G. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides. Antimicrobial Agents and Chemotherapy 1996; 40: 2337-2344.

  14. Hanecak R, Brown-Driver V, Foz MC, Azad RF, Furusako S, Nozaki C, Ford C, et al. Antisense oligonucleotide inhibition of hepatitis C virus gene expression and transformed hepatocytes. J Virol 1996; 70: 5203-5212.

  15. Hanecak R, Brown-Driver V, Fox MC, Azad RF, Furusako S, Nozaki C, Ford C, Sasmor H, Anderson KP. Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes. J Virol 1996; 70(8): 5203-12.

  16. McCaffrey AP, Meuse L, Karimi M, Contag CH, Kay MA. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 2003; 38(2): 503-8.

  17. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 15,98(12): 2720-8.

  18. Macejak DG, Jensen KL, Jamison SF, Domenico K, Roberts EC, Chaudhary N, von Carlowitz I, Bellon L, Tong MJ, Conrad A, Pavco PA, Blatt LM. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes. Hepatology 2000; 31(3): 769-76.

  19. Cocquerel L, Quinn ER, Flint M, Hadlock KG, Foung SK, Levy S. Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J Virol 2003; 77(2): 1604-9.

  20. Dagan S, Eren R. Therapeutic antibodies against viral hepatitis. Curr Opin Mol Ther 2003; 5(2): 148-55.

  21. Krawczynski K, Fattom A, Culver D. Passive transfer of Anti-HCV in chronic and acute HCV infections in chimpanzees-trials of experimental immune treatment. Hepatology 1999; 30: 423A.

  22. Houghton M. Strategies and Prospects for vaccination against the Hepatitis C viruses. Curr Top Microbiol Immunol 2000; 242: 327-329.

  23. Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette PJ, Bukh J, Purcell RH, Davis HL. DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 2002; 10; 20(27-28): 3263-71.

  24. Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 2002; (5): 680-3.




2020     |     www.medigraphic.com